Immune System Therapeutics granted new patent for new method of treating blood cancers

05-Sep-2011 - Australia

Immune System Therapeutics Limited (IST) announced it had secured patent protection in Australia for a new method of treating blood cancers that express a target called lambda myeloma antigen (LMA), which was discovered by IST research scientists.  This patent is a significant addition to IST’s growing platform of new treatments for cancer and other diseases.

The patent titled 'Target for B-cell disorders' covers the treatment of a broad range of blood cancers, involving the administration of antibodies that bind to LMA to prevent the growth of, or kill, the cancer cells found in  B cell lymphoproliferative diseases. IST is currently developing its second antibody candidate, IST-1458, for the treatment of blood cancers that display the LMA target.

The patent provides protection for the company’s platform technology until the year 2025

Immune System Therapeutics' Chief Executive Officer, Alan Liddle, said, “The granting of this patent confers further certainty and significantly increases the commercial value of IST’s promising new antibody platform for the treatment of a range of common human diseases.

“IST’s growing patent portfolio is a major commercial asset that will help ensure long-term exclusive licensing rights and underpin our global commercial opportunities.

“It is another positive step towards achieving our business goal of developing a range of effective new medical treatments based on our significant portfolio of antibody platform technologies for a range of cancers and diseases with major unmet clinical needs.”

Other news from the department research and development

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous